Skip to main content

Enanta Pharmaceuticals Inc

ENTA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001177648

No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Enanta Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Enanta Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Enanta Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Rottinghaus Scott T.Chief Medical Officer23,787Aug 10, 20264
Carter Bruce L ADirector0Mar 13, 20261
Foletta Mark GDirector–Mar 13, 20261
Russell LesleyDirector–Mar 13, 20261
Peterson KristineDirector–Mar 13, 20261
Vance TerryDirector5,800Mar 13, 20261
Hata Yujiro SDirector–Mar 13, 20261
Luly Jay R.President and CEO871,871Feb 13, 20264
Or Yat SunChief Scientific Officer374,854Feb 13, 20264
Kowalsky Matthew PaulChief Legal Officer3,591Feb 13, 20262
Kieffer Tara LynnChief Product Strategy Officer33,925Feb 13, 20264
Luu BrendanChief Business Officer41,634Feb 13, 20264
Trout Harry R. IIISee Remarks16,348Dec 5, 20253
Capps Kathleen S.See Remarks8,377Dec 5, 20253
Mellett Paul JChief Fin. & Admin Officer95,884Feb 14, 20250
Gardiner Nathaniel S.Chief Legal Officer75,688Feb 27, 20240
Adda NathalieSr. VP & Chief Medical Officer34,982Apr 5, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 5, 2025 (view filing)Dec 5Same dayCapps Kathleen S.See RemarksSSale−323$14.23−$4.60K−3.7%8.38K after
Dec 5, 2025 (view filing)Dec 5Same dayTrout Harry R. IIISee RemarksSSale−542$14.23−$7.71K−3.2%16.3K after
Dec 5, 2025 (view filing)Dec 5Same dayRottinghaus Scott T.Chief Medical OfficerSSale−798$14.23−$11.4K−3.5%21.8K after
Dec 5, 2025 (view filing)Dec 5Same dayLuu BrendanChief Business OfficerSSale−1.39K$14.23−$19.8K−3.5%38.3K after
Dec 5, 2025 (view filing)Dec 5Same dayKieffer Tara LynnChief Product Strategy OfficerSSale−2.11K$14.23−$30.0K−6.4%30.6K after
Dec 5, 2025 (view filing)Dec 5Same dayOr Yat SunChief Scientific OfficerSSale−2.39K$14.23−$34.0K−0.6%371.4K after
Dec 5, 2025 (view filing)Dec 5Same dayLuly Jay R.President and CEOSSale−4.74K$14.23−$67.5K−0.5%858.0K after
Dec 3, 2025 (view filing)Dec 21 dayCapps Kathleen S.See RemarksSSale−207$13.96−$2.89K−2.3%8.70K after
Dec 3, 2025 (view filing)Dec 21 dayTrout Harry R. IIISee RemarksSSale−380$13.96−$5.30K−2.2%16.9K after
Feb 12, 2025 (view filing)Feb 12Same dayLuly Jay R.President and CEOPPurchase+45.0K$5.69+$256.1K+5.6%846.6K after
Dec 10, 2024 (view filing)Dec 64 daysKieffer Tara LynnChief Product Strategy OfficerSSale−2.28K$8.06−$18.4K−7.2%29.3K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysLuu BrendanChief Business OfficerSSale−2.28K$8.06−$18.4K−6.0%36.0K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysRottinghaus Scott T.Chief Medical OfficerSSale−866$8.06−$6.98K−4.6%17.9K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysOr Yat SunChief Scientific OfficerSSale−2.59K$8.06−$20.9K−0.7%369.1K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysMellett Paul JChief Fin. & Admin OfficerSSale−2.59K$8.06−$20.9K−2.7%91.7K after10b5-1
Dec 10, 2024 (view filing)Dec 64 daysLuly Jay R.President and CEOSSale−5.14K$8.06−$41.4K−0.6%801.6K after10b5-1
Jul 15, 2024 (view filing)Jul 11-154 daysRottinghaus Scott T.Chief Medical OfficerSSale−11.9K$15.97−$190.7K−35.5%21.7K after3 lots10b5-1
Jun 17, 2024 (view filing)Jun 17Same dayKieffer Tara LynnChief Product Strategy OfficerSSale−7.27K$12.33−$89.6K−18.3%32.3K after10b5-1
Dec 15, 2023 (view filing)Dec 132 daysVance TerryDirectorSSale−15.3K$9.12−$139.5K−72.5%5.80K after
Dec 6, 2023 (view filing)Dec 51 dayLuu BrendanSr. VP, Business Dev.SSale−2.13K$9.63−$20.5K−5.5%36.7K after
Dec 6, 2023 (view filing)Dec 51 dayKieffer Tara LynnSr. VP, New Prod. Strat. & DevSSale−2.13K$9.63−$20.5K−5.4%37.3K after
Dec 6, 2023 (view filing)Dec 51 dayGardiner Nathaniel S.Sr. VP & General CounselSSale−2.41K$9.63−$23.2K−3.4%68.2K after
Dec 6, 2023 (view filing)Dec 51 dayRottinghaus Scott T.Sr. VP & CMOSSale−534$9.63−$5.14K−2.0%26.5K after
Dec 6, 2023 (view filing)Dec 51 dayOr Yat SunSr. VP, R&D & CSOSSale−2.41K$9.63−$23.2K−0.6%370.7K after
Dec 6, 2023 (view filing)Dec 51 dayMellett Paul JSr. VP, Finance & Admin. & CFOSSale−2.41K$9.63−$23.2K−2.5%93.5K after
Dec 6, 2023 (view filing)Dec 51 dayLuly Jay R.President and CEOSSale−7.23K$9.63−$69.6K−0.9%806.8K after
Mar 17, 2023 (view filing)Mar 152 daysMellett Paul JTreasurer and CFOSSale−10.4K$44.43−$463.8K−9.7%97.6K after2 lots
Mar 17, 2023 (view filing)Mar 152 daysOr Yat SunSr. VP & CSOSSale−13.9K$44.45−$619.0K−3.6%374.7K after2 lots
Mar 14, 2023 (view filing)Mar 131 dayLuly Jay R.President and CEOSSale−27.9K$45.16−$1.26M−3.3%819.8K after3 lots
Feb 13, 2023 (view filing)Feb 94 daysMellett Paul JTreasurer and CFOSSale−5.00K$53.76−$268.8K−5.7%83.5K after2 lots
Dec 16, 2022 (view filing)Dec 16Same dayLuly Jay R.President and CEOSSale−30.0K$44.72−$1.34M−3.7%773.8K after3 lots
Apr 5, 2022 (view filing)Apr 1-44 daysAdda NathalieSr. VP & Chief Medical OfficerSSale−83.3K$71.60−$5.97M−70.4%35.0K after6 lots
Mar 22, 2022 (view filing)Mar 211 dayCarter Bruce L ADirectorSSale−6.00K$67.83−$407.0K−100.0%0 after4 lots
Mar 3, 2022 (view filing)Mar 1-22 daysAdda NathalieSr. VP & Chief Medical OfficerSSale−36.8K$70.20−$2.58M−51.3%35.0K after3 lots
Jan 13, 2022 (view filing)Jan 112 daysAdda NathalieSr. VP & Chief Medical OfficerSSale−12.5K$70.13−$879.1K−27.6%32.9K after
Dec 3, 2021 (view filing)Dec 12 daysAdda NathalieSr. VP & Chief Medical OfficerSSale−13.5K$86.35−$1.17M−29.1%32.9K after7 lots
Nov 2, 2021 (view filing)Nov 11 dayAdda NathalieSr. VP & Chief Medical OfficerSSale−9.55K$84.89−$810.4K−26.2%26.9K after3 lots
Oct 13, 2021 (view filing)Oct 8-115 daysAdda NathalieSr. VP & Chief Medical OfficerSSale−17.5K$70.15−$1.23M−39.4%26.9K after2 lots
Sep 17, 2021 (view filing)Sep 152 daysLuly Jay R.President and CEOSSale−4.52K$59.06−$266.7K−0.7%677.0K after